ESC 365 - What is the benefit risk ratio of combination therapy?

What is the benefit risk ratio of combination therapy?

Session: Combination therapy in dyslipidaemia. What is new in Europe?

Topic: Epidemiology, lipids

Speaker: Doctor C. Aguiar (Lisbon, PT)

Sponsored by Abbott

Event: ESC CONGRESS 2014

About the speaker

Doctor Carlos Aguiar

Hospital Santa Cruz, Lisbon (Portugal)

15 presentations

14 followers

5 more presentations in this session

Introduction - Combination therapy in dyslipidaemia. What is new in Europe?

What is atherogenic dyslipidaemia? Does it really exist?

Speaker: Professor M. Krempf (Nantes, FR)

Is LDL-C lowering treatment enough to eliminate CV risk linked with atherogenic dyslipideamia?

Speaker: Professor C. Vlachopoulos (Athens, GR)

How can we improve compliance in patients with atherogenic dyslipidaemia?

Speaker: Professor M. Hermans (Brussels, BE)

Conclusion - Combination therapy in dyslipidaemia. What is new in Europe?

Access the full session

Combination therapy in dyslipidaemia. What is new in Europe?

Speakers: Doctor C. Aguiar, Professor M. Krempf, Professor C. Vlachopoulos, Professor M. Hermans

About the event

ESC CONGRESS 2014

30 August - 3 September 2014

Sessions Presentations

ESC 365 is supported by